Shaun Fleming

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri et al. · Blood · 2020 · 649 citations · Full text

Medicine, Oncology, Pharmacology +9

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Vinod Pullarkat, Norman J. Lacayo, Elias Jabbour et al. · Cancer Discovery · 2021 · 288 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Chong Chyn Chua, Andrew W. Roberts, John Reynolds et al. · Journal of Clinical Oncology · 2020 · 190 citations

Medicine, Oncology, Pharmacotherapy +17

Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Ghayas C. Issa, Ibrahim Aldoss, Michael J. Thirman et al. · Journal of Clinical Oncology · 2024 · 184 citations · Full text

Medicine, Oncology, Pharmacology +12

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Silvia Ling, Edwin Lau, Ammira Al-Shabeeb et al. · Haematologica · 2011 · 129 citations · Full text

Medicine, Biochemistry, Oncology +13